173 related articles for article (PubMed ID: 15346697)
21. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
22. Heart failure in a breast cancer survivor.
Moore S
Oncol Nurs Forum; 2012 Mar; 39(2):147-50. PubMed ID: 22374488
[No Abstract] [Full Text] [Related]
23. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
24. Reversible doxorubicin-induced congestive heart failure.
Cohen M; Kronzon I; Lebowitz A
Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
[TBL] [Abstract][Full Text] [Related]
25. Exercise echocardiography reflects cumulative anthracycline exposure during childhood.
Smibert E; Carlin JB; Vidmar S; Wilkinson LC; Newton M; Weintraub RG
Pediatr Blood Cancer; 2004 Jun; 42(7):556-62. PubMed ID: 15127409
[TBL] [Abstract][Full Text] [Related]
26. Role of mtDNA lesions in anthracycline cardiotoxicity.
Lebrecht D; Walker UA
Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
[TBL] [Abstract][Full Text] [Related]
27. [Myocardial disease due to external cause].
Okada Y
Nihon Rinsho; 2007 May; 65 Suppl 5():470-3. PubMed ID: 17571421
[No Abstract] [Full Text] [Related]
28. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines.
van Dalen EC; van der Pal HJ; van den Bos C; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Oct; 42(15):2549-53. PubMed ID: 16919450
[TBL] [Abstract][Full Text] [Related]
29. Acute cardiac functional and morphological changes after Anthracycline infusions in children.
Ganame J; Claus P; Eyskens B; Uyttebroeck A; Renard M; D'hooge J; Gewillig M; Bijnens B; Sutherland GR; Mertens L
Am J Cardiol; 2007 Apr; 99(7):974-7. PubMed ID: 17398195
[TBL] [Abstract][Full Text] [Related]
30. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
31. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
32. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
[TBL] [Abstract][Full Text] [Related]
33. Surgical treatment of doxorubicin-induced heart failure.
Christiansen S
Thorac Cardiovasc Surg; 2010 Feb; 58(1):8-10. PubMed ID: 20072969
[TBL] [Abstract][Full Text] [Related]
34. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
35. [Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis].
Safonova SA; Gershanovich ML; Punanov IuA
Vopr Onkol; 2006; 52(5):590-2. PubMed ID: 17168373
[No Abstract] [Full Text] [Related]
36. Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.
Kuch M; Janiszewski M; Mamcarz A; Cudnoch-Jedrzejewska A; Dłuzniewski M
Med Sci Monit; 2009 Jun; 15(6):PH40-8. PubMed ID: 19478711
[TBL] [Abstract][Full Text] [Related]
37. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.
Rudzinski T; Ciesielczyk M; Religa W; Bednarkiewicz Z; Krzeminska-Pakula M
Europace; 2007 May; 9(5):278-80. PubMed ID: 17383986
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline-induced heart failure.
van Dalen EC
Nat Clin Pract Oncol; 2007 Dec; 4(12):E1. PubMed ID: 18037871
[No Abstract] [Full Text] [Related]
40. [The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy].
Katamadze NA; Lartsuliani KP; Begishvili NN; Dundua KhV; Kiknadze MP
Georgian Med News; 2006 Jan; (130):61-4. PubMed ID: 16510915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
